Skip to main
TEM

TEM Stock Forecast & Price Target

TEM Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Tempus AI Inc has demonstrated significant financial growth, with total revenue increasing by 84.7% year-over-year, largely driven by a remarkable 117.2% rise in genomics revenue to $252.9 million. The company's laboratory test offerings, including the xF liquid biopsy assay and xT CDx test, are expected to see higher average selling prices, bolstered by expected additional pharma contracts and improved reimbursements for its MRD products. Furthermore, oncology testing volume increased by 27%, indicating a robust demand for Tempus' Intelligent Diagnostics solutions, which utilize AI technology to enhance the accuracy and personalization of laboratory testing.

Bears say

Tempus AI Inc. experienced a significant decline in gross margins from 76.8% to 69.7% in its Data & Other segment, which raises concerns about its ability to maintain profitability amidst increasing operational costs and potential market challenges. The company has also incurred substantial losses since its inception and carries a considerable debt load of $518.8 million, suggesting ongoing financial strain and a risk of sustained losses in the future. Additionally, operating cash flow decreased by $168.5 million year-over-year, indicating potential liquidity issues that may hinder investments in growth and innovation, further complicating its path to achieving sustainable profitability.

TEM has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tempus AI Inc (TEM) Forecast

Analysts have given TEM a Buy based on their latest research and market trends.

According to 11 analysts, TEM has a Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $79.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $79.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tempus AI Inc (TEM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.